Sixteen-year longitudinal changes in serum prostate-specific antigen levels: The Olmsted County study

Mayo Clinic Proceedings

Volumn 87, Issue 1, 2012, Pages 34-40

  Jacobsen, Steven J ^a   Jacobson, Debra J ^b   McGree, Michaela E ^b   St Sauver, Jennifer L ^b   Klee, George G ^b   Girman, Cynthia J ^b,c   Lieber, Michael M ^b  

^a KAISER PERMANENTE   (United States)

^b MAYO CLINIC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM EXAMINATION; MEDICAL PRACTICE; POPULATION RESEARCH; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; TREND STUDY; UNITED STATES;

EID: 84855712723     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2011.09.002     Document Type: Article

References (36)

1. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156-1161.
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-916. (Pubitemid 17147932)
3. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2, pt 1):407-413.
4. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267(16):2215-2220.
5. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol. 2004;172(1):90-93. (Pubitemid 41615045)
6. McGreevy K, Rodgers K, Lipsitz S, Bissada N, Hoel D. Impact of race and baseline PSA on longitudinal PSA. Int J Cancer. 2006;118(7):1773-1776. (Pubitemid 43376442)
7. Yu X, Loeb S, Roehl KA, Han M, Catalona WJ. The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol. 2007;177(4):1298-1302; discussion 1301-1302.
8. Loeb S, Roehl KA, Nadler RB, Yu X, Catalona WJ. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol. 2007;178(6):2348-2352; discussion 2352-2353.
9. Carter HB, Pearson JD, Waclawiw Z, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology. 1995;45(4):591-596.
10. Hakimi AA, Rabbani F. Editorial comment. Urology. 2011;77(1):147; author reply 148.
11. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27(3):398-403.
12. Yu X, Han M, Loeb S, et al. Comparison of methods for calculating prostate specific antigen velocity. J Urol. 2006;176(6, pt 1):2427-2431; discussion 2431.
13. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529-534. (Pubitemid 43898816)
14. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125-135.
15. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98(21):1521-1527. (Pubitemid 44680903)
16. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150(1):85-89. (Pubitemid 23175978)
17. Jacobsen SJ, Guess HA, Panser L, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms: The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med. 1993;2(7):729-735.
18. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270(7):860-864. (Pubitemid 23234116)
19. Panser LA, Chute CG, Guess HA, et al. The natural history of prostatism: the effects of non-response bias. Int J Epidemiol. 1994;23(6):1198-1205.
20. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121-130.
21. Perrin P. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence. Eur Urol. 2006;49(3):418-419. (Pubitemid 43259545)
22. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol. 2009;56(5):753-760.
23. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011;103(6):462-469.
24. De Biasi F, Londero D, Praturlon S, Di Donna A, Feruglio GA, Guerra UP. Longitudinal evaluation of prostate-specific antigen levels in a case-control study. Eur Urol. 1996;29(2):184-188. (Pubitemid 26059422)
25. Berger AP, Deibl M, Steiner H, et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate. 2005;64(3):240-245. (Pubitemid 40980865)
26. Bosch JL, Tilling K, Bohnen AM, Donovan JL; Krimpen Study. Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study. Prostate. 2006;66(4):335-343. (Pubitemid 43346944)
27. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol. 1994;152(5, pt 2):1743-1748. (Pubitemid 24322619)
28. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American phase III clinical trial. Urol Clin North Am. 1993;20(4):627-636. (Pubitemid 24141155)
29. Jacobsen SJ, Lilja H, Klee GG, Wright GL Jr, Pettersson K, Oesterling JE. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology. 1994;44(4):512-518.
30. Jacobsen SJ, Klee GG, Lilja H, Wright GL Jr, Oesterling JE. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology. 1995;45(3):447-453.
31. Sokoll LJ, Witte DL, Klee GG, Chan DW. Redesigned proficiency testing materials improve survey outcomes for prostate-specific antigen; a College of American Pathologists Ligand Assay Survey tool. Arch Pathol Lab Med. 2000;124(11):1608-1613.
32. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006;52(1):59-64. (Pubitemid 43032467)
33. Loeb S, Chan DW, Sokoll L, et al. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol. 2008;180(5):1959-1962; discussion 1962-1963.
34. Gades NM, Jacobson DJ, McGree ME, et al. Dropout in a longitudinal, cohort study of urologic disease in community men. BMC Med Res Methodol. December 14, 2006;6:58.
35. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481-487. (Pubitemid 27327692)
36. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999;162(4):1301-1306. (Pubitemid 29428567)